The reason we don't want to parse things out at the moment is that as things are unfolding, the future of medicine is that everything is essentially going to become a rare disease.
We used to think that we'd treat all lung cancer the same way. Now, as we go through the biomolecular basis of cancer, you could end up with hundreds of different treatments for that lung cancer, which means that we now have small groups of patients who, in a sense, meet the criteria for a rare disease. If very few people have that kind of lung cancer in Canada, there's that specific treatment.
The future of all of medicine is really going to be very individualized and a “very rare disease per person” approach. We needed a robust approach to deal with all medicines, regardless of how many people are being treated with it, and to make sure that the health care system is going to be sustainable when we move to that environment. We are rapidly moving towards that environment.